Regeneus

Karolis Rosickas, CEO
Sydney, Australia
(ASX: RGS)
Regeneus is a clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. www.regeneus.com.au



By using this website you agree to accept our Privacy Policy and Terms & Conditions